Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder

Suppes, Trisha; Eudicone, James M.; McQuade, Robert D.; Pikalov, Andrei; Carlson, Berit X.

doi:10.1016/j.jad.2007.08.015

Cited by 72 publications

(51 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recent studies suggest that the efficacy of SGAs is established both as monotherapy and as add-on therapy to mood stabilizers [384,435,461]. The general picture suggests that antimanic agents are roughly equal in efficacy against acute mania [384,486]; however, complete meta-analytic data are available only for aripiprazole [169,475]. Olanzapine and aripiprazole are confirmed to be efficacious against psychotic features [45, 169,475].…”

Section: Meta-analytic Studiesmentioning

confidence: 99%

“…The general picture suggests that antimanic agents are roughly equal in efficacy against acute mania [384,486]; however, complete meta-analytic data are available only for aripiprazole [169,475]. Olanzapine and aripiprazole are confirmed to be efficacious against psychotic features [45, 169,475]. Olanzapine is also efficacious in patients with prior history of good or poor response to lithium or anticonvulsants [43], and its overall response rate is clearly superior to placebo (55 vs. 29.5 %) [106].…”

Section: Meta-analytic Studiesmentioning

confidence: 99%

“…Concerning the treatment of the acute phase, aripiprazole was significantly more efficacious against both manic and depressive symptoms than placebo [425] with response of manic symptoms being unrelated to baseline depressive severity [278,425,475].…”

Section: Treatment Of Mixed Episodesmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

Fountoulakis

Kasper

Andreassen

et al. 2012

Eur Arch Psychiatry Clin Neurosci

118

View full text Add to dashboard Cite

Section: Meta-analytic Studiesmentioning

confidence: 99%

Section: Meta-analytic Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

Fountoulakis

Kasper

Andreassen

et al. 2012

Eur Arch Psychiatry Clin Neurosci

118

View full text Add to dashboard Cite

“…Regarding aripiprazole, the adult bipolar literature suggests that aripiprazole monotherapy is efficacious in the treatment of mania in both the acute and maintenance phase (Vieta et al 2005;Keck et al 2007). In addition, a recent analysis of 516 adult bipolar I patients found that aripiprazole improved outcomes, even in groups that are traditionally treatment resistant (Suppes et al 2008). Regarding the pediatric literature, two chart reviews (Barzman et al 2004;Biederman et al 2005a) and one small open-label trial (Biederman et al 2007b) support the efficacy and safety of aripiprazole in the treatment of pediatric bipolar disorder.…”

Section: Potter Et Almentioning

confidence: 99%

Prescribing Patterns for Treatment of Pediatric Bipolar Disorder in a Specialty Clinic

Potter

Liu

Monuteaux

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The aim of this study was to describe prescribing practices in the treatment of pediatric bipolar disorder in a university practice setting. Method: A retrospective chart review was performed on 53 youths diagnosed using Diagnostic and Statistical Manual of Mental Disorders, 4 th edition (DSM-IV), criteria with bipolar spectrum disorder under the active care of child psychiatrists practicing in a pediatric psychopharmacology specialty clinic. Current medications, doses, and related adverse events were recorded. Clinicians were asked to provide a target disorder (bipolar mania=mixed state, depression, attention deficit hyperactivity disorder [ADHD], or anxiety) for each medication to the best of their ability. The Clinical Global ImpressionsSeverity (CGI-S) scale was used to measure severity of each disorder before treatment and the Clinical Global ImpressionsImprovement (CGI-I) was used to quantify the magnitude of improvement with treatment. Meaningful improvement of the disorder was defined by CGI-I score of 1 or 2. Results: The mean number of psychotropic medications per patient was 3.0 AE 1.6. A total of 68% of patients were treated for co-morbid disorders; 23% of patients were treated with monotherapy, primarily with second-generation antipsychotics. Mania improved in 80% of cases, mixed state improved in 57% of cases, ADHD improved in 56% of cases, anxiety improved in 61% of cases, and depression improved in 90% of cases. Conclusion: The management of pediatric bipolar disorder often requires multiple medications. For the treatment of mania= mixed states, clinicians prescribed second-generation antipsychotics more frequently than mood stabilizers, especially in the context of monotherapy. Co-morbidity was a frequent problem with moderate success obtained with combined pharmacotherapy approaches. Further psychosocial strategies to augment pharmacotherapy may improve outcome while reducing the medication burden in pediatric bipolar disorder.

show abstract

“…Men and women, and patients in different age groups, 18-40 and 41-55, showed no difference in their improvement. 28 Many patients with bipolar disorder require treatment with more than one mood stabilizer, due to effi cacy or tolerability concerns. In fact, several guidelines for the treatment of severe mania recommend the combination of a traditional mood stabilizer with an atypical antipsychotic.…”

Section: Maniamentioning

confidence: 99%

Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole

Bastiaens

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Bipolar disorder is a common and complex condition, starting early in life and continuing throughout the life cycle. Most people suffering from bipolar disorder manifest other problems as well, including metabolic disturbances, cardiovascular disease, anxiety disorders, substance use disorders, attention defi cit hyperactivity disorder, and borderline personality disorder, among others. The treatment of bipolar disorder needs to be conceptualized within this context of early onset, chronic course, and signifi cant co-morbidity. Because of its unique mode of action, its effi cacy and its good tolerability profi le, aripiprazole is well placed among the different treatment options to benefi t the patient with bipolar disorder. This article will focus on aripiprazole's pharmacology, effi cacy, effectiveness, and tolerability from a clinical perspective, while considering the complexities of bipolar disorder.

show abstract

Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder

Cited by 72 publications

References 28 publications

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

Prescribing Patterns for Treatment of Pediatric Bipolar Disorder in a Specialty Clinic

Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole

Contact Info

Product

Resources

About